Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Roland Simon is active.

Publication


Featured researches published by Roland Simon.


Addiction | 2016

The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015

Jane Mounteney; Paul Griffiths; Roumen Sedefov; André Noor; Julian Vicente; Roland Simon

AIM A central task for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is to produce an annual report of the latest data available on drug demand and drug supply in Europe. This paper is intended to facilitate a better understanding of, and easier access to, the main quantitative European level data sets available in 2015. METHODS The European reporting system formally covers all 28 European Union (EU) Member States, Norway and Turkey and incorporates multiple indicators alongside an early warning system (EWS) on uncontrolled new psychoactive substances (NPS). While epidemiological information is based largely on registries, surveys and other routine data reported annually, the EWS collects case-based data on an ongoing basis. The 2015 reporting exercise is centred primarily on a set of standardized reporting tools. RESULTS The most recent data provided by European countries are presented, including data on drug use, drug-related morbidity and mortality, treatment demand, drug markets and new psychoactive substances, with data tables provided and methodological information. A number of key results are highlighted for illustrative purposes. Drug prevalence estimates from national surveys since 2012 (last year prevalence of use among the 15-34 age band) range from 0.4% in Turkey to 22.1% in France for cannabis, from 0.2% in Greece and Romania to 4.2% in the United Kingdom for cocaine, from 0.1% in Italy and Turkey to 3% in the Czech Republic and the United Kingdom for ecstasy, and from 0.1% or less in Romania, Italy and Portugal to 2.5% in Estonia for amphetamine. Declining trends in new HIV detections among people who inject drugs are illustrated, in addition to presentation of a breakdown of NPS reported to the EU early warning system, which have risen exponentially from fewer than 20 a year between 2005 and 2008, to 101 reported in 2014. CONCLUSIONS Structured information is now available on patterns and trends in drug consumption in Europe, which permits triangulation of data from different sources and consideration of methodological limitations. Opioid drugs continue to place a burden on the drug treatment system, although both new heroin entrants and injecting show declines. More than 450 new psychoactive substances are now monitored by the European early warning system with 31 new synthetic cathinones and 30 new synthetic cannabinoid receptor agonists notified in 2014.


International Journal of Drug Policy | 2017

New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe

Alessandro Pirona; Alessandra Bo; Dagmar Hedrich; Marica Ferri; Nadine van Gelder; Isabelle Giraudon; Linda Montanari; Roland Simon; Jane Mounteney

BACKGROUND The availability of new psychoactive substances (NPS) in Europe has rapidly increased over the last decade. Although prevalence levels of NPS use remain low in the general European population, there are serious concerns associated with more problematic forms of use and harms in particular populations and settings. It has thus become a priority to formulate and implement effective public health responses. However, considerable knowledge gaps remain on current practices as well as on the challenges and needs of European health professionals who are responding to use and harms caused by these substances. The aim of this study was to explore current health responses to NPS, and highlight key issues in order to inform planning and implementation of adequate responses. METHODS This scoping study was based on a targeted multi-source data collection exercise focusing on the provision of health and drug interventions associated with NPS use and harms, in selected intervention settings across Europe. RESULTS Findings revealed that in the absence of specific evidence, health professionals across most intervention settings rely primarily on acquired expertise with traditional drugs when addressing NPS-related harms. This study also identified a gap in the availability and access to timely and reliable information on NPS to users and health professionals. Health professionals in sexual health settings and custodial settings in contact with certain risk groups reported particular challenges in responding to NPS-related harms. CONCLUSION Immediate investments are required in expanding substance identification capabilities, competence building among professionals and dissemination of risk information among relevant stakeholders. The risks of neglecting under-served risk populations and failure to address the information needs of health professionals and users on NPS harms in a context of rapid changing drug markets in Europe may have unforeseeable consequences at societal level.


Drugs-education Prevention and Policy | 2011

Gender and regional differences in client characteristics among substance abuse treatment clients in the Europe

Linda Montanari; Marco Serafini; Etienne Maffli; Katerina Kontogeorgiou; Wil Kuijpers; Anton Ouwehand; Maria Pouloudi; Roland Simon; Maria Spyropoulou; Bela Studnickova; V. Anna Gyarmathy

Aims: To assesses the extent of the gender gap among the treated population of drug users across Europe. Methods: This analysis reports data on 363,170 clients from 4647 treatment units in 23 countries (22 European Union member states and Switzerland). Findings: Overall, males outnumber females by four, but the gender ratio varies not only by geographical region/country, but also by drug. In the majority of countries, the most common primary problem drug is opioids, and the overall gender ratio mirrors the gender ratio of opioid users. In some countries, a considerable proportion of treated drug users have cannabis and stimulants (cocaine/amphetamines/methamphetamines) as primary problem drugs. Stimulants other than cocaine and other drugs have lower, while cannabis has a higher than overall male-to-female gender ratio. Conclusions: The very high male-to-female gender ratios may reveal differential access to treatment. Our findings highlight the need to assess access to treatment for women problem drug users and to make women-focussed programmes more available to increase the proportion of women in drug treatment programmes across Europe.


European Neuropsychopharmacology | 2012

Corrigendum to “Cost of disorders of the brain in Europe 2010” [Eur. Neuropsychopharmacol. 21 (2011) 718–779]

Anders Gustavsson; Mikael Svensson; Frank Jacobi; Christer Allgulander; Jordi Alonso; Ettore Beghi; R. Dodel; Mattias Ekman; Carlo Faravelli; Laura Fratiglioni; Brenda Gannon; David Hilton Jones; Pout Jennum; Albena Jordanova; Linus Jönsson; Korinna Karampampa; Martin Knapp; Gisela Kobelt; Tobias Kurth; Roselind Lieb; Mattias Linde; Christina Ljungcrantz; Andreas Maercker; Beatrice Melin; Massimo Moscarelli; Amir Musayev; Fiona Norwood; Martin Preisig; Maura Pugliatti; Juergen Rehm

Corrigendum to “Cost of disorders of the brain in Europe 2010” [Eur. Neuropsychopharmacol. 21 (2011) 718–779]


Drugs-education Prevention and Policy | 2018

Quality assurance in drug demand reduction in European countries: an overview

Marica Ferri; Sónia Dias; Alessandra Bo; Danilo Ballotta; Roland Simon; Giuseppe Carrà

Abstract Background: The EMCDDA, through its network of National Focal Points, collects information on the quality assurance systems for drugs-related interventions across European countries. European National Drug Strategies include recommendations for systems and approaches for the assurance of the quality of interventions. Methods: We searched National Drug Strategies for elements related to quality assurance in drug demand reduction and summarised information through questionnaires administered to the EMCDDA Network of National Focal Points. Results: In total, 15 National Drug Strategies and 60 questionnaires were analysed. Almost all the strategies include quality-related topics. Frequently, the Ministry of Health leads quality assurance although sometimes jointly with the Ministries of Education, Labour, Family and Social Welfare. Accreditation systems are common, but implemented in different ways. Training and education are widely provided, for the vast majority of countries, consisting of short-term training to keep professionals updated. Guidelines and Standards are gathering momentum as the major tools for the implementation of evidence-based recommendations and are usually available across countries. Conclusions: Although the evidence base for interventions in drug demand reduction is becoming available and accepted, attention needs to be given to implementation issues. The European countries are rapidly moving towards paying greater attention to the quality of interventions.


Harm Reduction Journal | 2017

Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study

Lucas Wiessing; Marica Ferri; Vendula Běláčková; Patrizia Carrieri; Samuel R. Friedman; Cinta Folch; Kate Dolan; Brian Galvin; Peter Vickerman; Jeffrey V. Lazarus; Viktor Mravčík; Mirjam Kretzschmar; Vana Sypsa; Ana Sarasa-Renedo; Anneli Uusküla; Dimitrios Paraskevis; Luís Mendão; Diana Rossi; Nadine van Gelder; Luke Mitcheson; Letizia Paoli; Cristina Diaz Gomez; Maitena Milhet; Nicoleta Dascalu; Jonathan Knight; Gordon Hay; Eleni Kalamara; Roland Simon; Catherine Comiskey; Carla Rossi

Background and aimsDespite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the historical development of successful epidemiological indicators and to present a framework for extending them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at international, national or subnational levels. The ultimate aim is to improve these services in order to reduce health and social problems among people who use drugs, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection, crime and legal problems, overdose (death) and other morbidity and mortality.Methods and resultsThe framework was developed collaboratively using consensus methods involving nominal group meetings, review of existing quality standards, repeated email commenting rounds and qualitative analysis of opinions/experiences from a broad range of professionals/experts, including members of civil society and organisations representing people who use drugs. Twelve priority candidate indicators are proposed for opioid agonist therapy (OAT), needle and syringe programmes (NSP) and generic cross-cutting aspects of harm reduction (and potentially other drug) services. Under the specific OAT indicators, priority indicators included ‘coverage’, ‘waiting list time’, ‘dosage’ and ‘availability in prisons’. For the specific NSP indicators, the priority indicators included ‘coverage’, ‘number of needles/syringes distributed/collected’, ‘provision of other drug use paraphernalia’ and ‘availability in prisons’. Among the generic or cross-cutting indicators the priority indicators were ‘infectious diseases counselling and care’, ‘take away naloxone’, ‘information on safe use/sex’ and ‘condoms’. We discuss conditions for the successful development of the suggested indicators and constraints (e.g. funding, ideology). We propose conducting a pilot study to test the feasibility and applicability of the proposed indicators before their scaling up and routine implementation, to evaluate their effectiveness in comparing service coverage and quality across countries.ConclusionsThe establishment of an improved set of validated and internationally agreed upon best practice indicators for monitoring harm reduction service will provide a structural basis for public health and epidemiological studies and support evidence and human rights-based health policies, services and interventions.


Suchttherapie | 2010

Nachrichten aus der EBDD

Roland Simon; Roumen Sedefov

Mindestens seit 2006 werden, vorwiegend im Internet, rauchbare Krautermischungen unter Namen wie «Spice» oder ahnlichem angeboten. Offiziell als «nicht fur den menschlichen Konsum geeignete Rauchermischungen» beschrieben, kursierten im Internet und anderswo bald Informationen uber Cannabis ahnliche Effekte dieser Produkte. Die Europaische Beobachtungsstelle fur Drogen und Drogensucht (EBDD) hat im Rahmen ihres Fruhwarnsystems Informationen zu diesem Thema gesammelt, die durch eine Erhebung unter 30 Nationalen Knotenpunkten und Recherchen in Internetforen erganzt wurden. Der vorliegende Text ist eine kurze Zusammenfassung der daraus resultierenden Publikation (EMCDDA, 2009). Der Begriff «Spice» wird hier als Gattungsbegriff verwendet, da Veranderungen im Markt und in der Rechtslage zu einer Vielzahl von Namen fur ahnliche Produkte gefuhrt haben.


European Neuropsychopharmacology | 2011

The size and burden of mental disorders and other disorders of the brain in Europe 2010

Hans-Ulrich Wittchen; Frank Jacobi; Jürgen Rehm; Anders Gustavsson; Mikael Svensson; Bengt Jönsson; Jes Olesen; Christer Allgulander; Jordi Alonso; Carlo Faravelli; Laura Fratiglioni; Poul Jennum; Roselind Lieb; Andreas Maercker; J. van Os; Martin Preisig; Luis Salvador-Carulla; Roland Simon; Hans-Christoph Steinhausen


European Neuropsychopharmacology | 2011

Cost of disorders of the brain in Europe 2010

Anders Gustavsson; Mikael Svensson; Frank Jacobi; Christer Allgulander; Jordi Alonso; Ettore Beghi; R. Dodel; Mattias Ekman; Carlo Faravelli; Laura Fratiglioni; Brenda Gannon; David Hilton Jones; Poul Jennum; Albena Jordanova; Linus Jönsson; Korinna Karampampa; Martin Knapp; Gisela Kobelt; Tobias Kurth; Roselind Lieb; Mattias Linde; Christina Ljungcrantz; Andreas Maercker; Beatrice Melin; Massimo Moscarelli; Amir Musayev; Fiona Norwood; Martin Preisig; Maura Pugliatti; Juergen Rehm


British Journal of Psychiatry | 2015

Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction

John Strang; Teodora Groshkova; Ambros Uchtenhagen; Wim van den Brink; C. Haasen; Martin T. Schechter; Nicholas Lintzeris; Jimmy D. Bell; Alessandro Pirona; Eugenia Oviedo-Joekes; Roland Simon; Nicola Metrebian

Collaboration


Dive into the Roland Simon's collaboration.

Top Co-Authors

Avatar

Alessandro Pirona

European Monitoring Centre for Drugs and Drug Addiction

View shared research outputs
Top Co-Authors

Avatar

Lucas Wiessing

European Monitoring Centre for Drugs and Drug Addiction

View shared research outputs
Top Co-Authors

Avatar

Marica Ferri

European Monitoring Centre for Drugs and Drug Addiction

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Griffiths

European Monitoring Centre for Drugs and Drug Addiction

View shared research outputs
Top Co-Authors

Avatar

Frank Jacobi

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge